498 related articles for article (PubMed ID: 27787906)
21. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
22. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
Front Neurol; 2019; 10():1008. PubMed ID: 31608004
[No Abstract] [Full Text] [Related]
23. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
24. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
25. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
26. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
27. CSF chitinase proteins in amyotrophic lateral sclerosis.
Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
29. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
30. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
[TBL] [Abstract][Full Text] [Related]
31. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
32. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
33. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
35. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Gunnarsson M; Malmeström C; Axelsson M; Sundström P; Dahle C; Vrethem M; Olsson T; Piehl F; Norgren N; Rosengren L; Svenningsson A; Lycke J
Ann Neurol; 2011 Jan; 69(1):83-9. PubMed ID: 21280078
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.
Zhong X; Wang H; Dai Y; Wu A; Bao J; Xu W; Cheng C; Lu Z; Qiu W; Hu X
J Neuroimmunol; 2011 Dec; 240-241():104-8. PubMed ID: 22036953
[TBL] [Abstract][Full Text] [Related]
38. Multiple sclerosis: Biomarkers and genetic variants reflect disease course in multiple sclerosis.
Wood H
Nat Rev Neurol; 2016 Oct; 12(10):553. PubMed ID: 27615421
[No Abstract] [Full Text] [Related]
39. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
[TBL] [Abstract][Full Text] [Related]
40. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
